Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

JPMorgan Chase Lowers Syndax Pharmaceuticals Target Price to $40.00

Guavy AI Editorial Team
Instruments
JPM
Share

Syndax Pharmaceuticals (NASDAQ:SNDX) had its target price lowered by JPMorgan Chase & Co. from $44.00 to $40.00 in a research report issued on Tuesday.

The brokerage currently has an 'overweight' rating on the stock, indicating a potential upside of 98.12% from the company's current price of $20.19.

This is not the only change to the target price; UBS Group restated a 'buy' rating and Barclays increased their price objective from $35.00 to $37.00.

More on Stocks

Stocks just now

Hormuz Uncertainty and Intel Share Sale Weigh on Wall Street

Stocks just now

Salesforce Loses $600k Contract to In-House AI CRM

Stocks 3m ago

UNH Medicare Growth Surpasses Expectations, More Upside Ahead

Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy